COMMUNIQUÉS West-GlobeNewswire

Reunion Neuroscience Announces First Patient Dosed in REKINDLE Phase 2 Clinical Trial of RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses
30/09/2025
-- AjD Represents an Area of Significant Unmet Need; No U.S. Food and Drug Administration (FDA)-Approved Therapies Available -- -- Following Positive Topline Data in RECONNECT Phase 2 Trial, Expect to Initiate Phase 3 [...]
Umoja Biopharma Announces that UB-VV111 Receives FDA Fast Track Designation for Relapsed/Refractory B-Cell Malignancies
30/09/2025
SEATTLE, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, announced today that the U.S. Food and Drug [...]
AssistRx Joins Second Annual Drug Channels Leadership Forum as Diamond Sponsor
30/09/2025
Invite-only event will address today’s most pressing healthcare system challenges ORLANDO, Fla., Sept. 30, 2025 (GLOBE NEWSWIRE) -- AssistRx , the advanced therapy initiation and patient solutions provider, today [...]
LifeMD Offers Ozempic® at $499 Per Month through Collaboration with Novo Nordisk
30/09/2025
Ozempic® is now available at this reduced price to eligible self-pay LifeMD patients NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced [...]
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
30/09/2025
VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is the first and only [...]
Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA
30/09/2025
Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments OAK RIDGE, TN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), [...]
Prenetics Announces CEO Danny Yeung Keynote at Token 2049 Singapore
30/09/2025
- Keynote: “IM8: The World’s Fastest-Growing Supplement Brand Powering Our Bitcoin Treasury - Prenetics currently holds 246 BTC with a NAV of $28M - Prenetics has $63.5m of cash 1 CHARLOTTE, N.C., Sept. 30, 2025 (GLOBE [...]
Catheter Precision, Inc. Announces Two New Patents to be Issued by USPTO
30/09/2025
FORT MILL, S.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac [...]
VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology
30/09/2025
Partnership combines Secarna’s OligoCreator® platform with VERAXA’s technology suite to create next-generation targeted therapies for autoimmune and inflammatory diseases ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
30/09/2025
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 30 September 2025 at 9.00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Pulselight appoints Sir Jonathan Van-Tam as an Advisor
30/09/2025
Sir Jonathan Van-Tam joins Pulselight to support its mission to transform the UK health system by reducing waiting lists, driving efficiencies and improving patient outcomes LONDON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- [...]
MSInsight se joint au projet PREDI-LYNCH, une initiative européenne pour permettre d’identifier plus tôt les porteurs du syndrome de Lynch, l’une des principales prédispositions héréditaires au cancer.
30/09/2025
Communiqué de presse Paris, 29 septembre 2025 – MSInsight, start-up française de médecine de précision en oncologie, annonce sa participation au projet européen PREDI-LYNCH, un consortium coordonné par l’Hôpital [...]
MSInsight Joins PREDI-LYNCH Project to Advance Non-Invasive Cancer Detection in Lynch Syndrome — Aligning With Hereditary Cancer Awareness Week
30/09/2025
Press Release Paris, September 2025 – MSInsight, a French precision oncology start-up, is proud to announce its participation in PREDI-LYNCH * , a six-year Horizon Europe consortium led by Oslo University Hospital. This [...]
Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress
30/09/2025
– Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites – – Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric receptor [...]
Dogecoin Cash Inc. (OTCQB:DOGP) Announces Special Distribution of DogeCoin Cash (MEMECOIN:DOG) to Shareholders
30/09/2025
MESQUITE, NV, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mesquite, NV — Dogecoin Cash Inc. (OTCQB:DOGP) today announced that its Board of Directors has approved a special distribution of DogeCoin Cash (MEMECOIN:DOG) to [...]
Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025
30/09/2025
Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025 Schlieren (Zürich), Switzerland – September 30, 2025 – Kuros Biosciences (“Kuros” or the “Company”), a leader in innovative [...]
Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update
30/09/2025
Cash position of CHF 2.3 million at end of H1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149 Indivior advanced [...]
Valneva annonce un taux de séroréponse de 95% quatre ans après une vaccination avec une seule dose du vaccin contre le chikungunya IXCHIQ®
30/09/2025
Persistance des anticorps chez les adultes âgés de 65 ans et plus, comparable à celle des jeunes adultes La durabilité de la réponse immunitaire est un avantage compétitif clé pour un vaccin ciblant une maladie [...]
Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®
30/09/2025
Long-lasting antibody persistence was comparable in older (65+) and younger adults Long-term antibody persistence is a key competitive advantage for a vaccine targeting unpredictable outbreak diseases like chikungunya [...]

Pages